$7.04
00.00%
Pre-Market: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Verrica Pharmaceuticals
VRCANASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Verrica Pharmaceuticals (NASDAQ:VRCA) Stock, Analyst Ratings, Price Targets, Forecasts
Verrica Pharmaceuticals Inc has a consensus price target of $12.29 based on the ratings of 7 analysts. The high is $20 issued by Brookline Capital on March 10, 2022. The low is $4 issued by RBC Capital on May 25, 2022. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Needham on May 16, 2024, May 14, 2024, and May 14, 2024, respectively. With an average price target of $15.33 between Needham, HC Wainwright & Co., and Needham, there's an implied 117.80% upside for Verrica Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
Needham
Jefferies
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Verrica Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2024 | Buy Now | 127.27% | Needham | Serge Belanger | → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 98.86% | HC Wainwright & Co. | Oren Livnat | $13 → $14 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 127.27% | Needham | Serge Belanger | $8 → $16 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | 13.64% | Needham | — | → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 13.64% | Needham | Serge Belanger | → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 84.66% | HC Wainwright & Co. | Oren Livnat | $12 → $13 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | 42.05% | Jefferies | Glen Santangelo | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 11/10/2023 | Buy Now | 13.64% | Needham | Serge Belanger | $10 → $8 | Maintains | Buy | Get Alert |
| 10/12/2023 | Buy Now | 70.45% | HC Wainwright & Co. | Oren Livnat | → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | Buy Now | 42.05% | Needham | Serge Belanger | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 42.05% | Needham | Serge Belanger | → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | Buy Now | 70.45% | HC Wainwright & Co. | Oren Livnat | $11 → $12 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | 98.86% | RBC Capital | Gregory Renza | $11 → $14 | Maintains | Outperform | Get Alert |
| 07/25/2023 | Buy Now | 42.05% | Needham | Serge Belanger | → $10 | Upgrade | Hold → Buy | Get Alert |
| 07/17/2023 | Buy Now | 56.25% | HC Wainwright & Co. | Oren Livnat | → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2023 | Buy Now | 42.05% | Jefferies | Glen Santangelo | → $10 | Initiates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 56.25% | RBC Capital | Gregory Renza | → $11 | Reiterates | → Outperform | Get Alert |
| 02/13/2023 | Buy Now | 56.25% | RBC Capital | Gregory Renza | $4 → $11 | Upgrade | Sector Perform → Outperform | Get Alert |
| 05/31/2022 | Buy Now | 70.45% | HC Wainwright & Co. | Oren Livnat | $20 → $12 | Maintains | Buy | Get Alert |
| 05/25/2022 | Buy Now | -43.18% | RBC Capital | Daniel Busby | $16 → $4 | Downgrade | Outperform → Sector Perform | Get Alert |
| 03/10/2022 | Buy Now | 184.09% | Brookline Capital | Kemp Dolliver | → $20 | Initiates | → Buy | Get Alert |
| 03/03/2022 | Buy Now | 155.68% | Needham | Serge Belanger | $20 → $18 | Maintains | Buy | Get Alert |
| 09/22/2021 | Buy Now | 184.09% | HC Wainwright & Co. | Oren Livnat | — | Maintains | Buy | Get Alert |
| 09/21/2021 | Buy Now | 127.27% | RBC Capital | Gregory Renza | — | Maintains | Outperform | Get Alert |
| 09/21/2021 | Buy Now | 184.09% | Needham | Serge Belanger | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Verrica Pharmaceuticals (VRCA) stock?
The latest price target for Verrica Pharmaceuticals (NASDAQ:VRCA) was reported by Needham on May 16, 2024. The analyst firm set a price target for $16.00 expecting VRCA to rise to within 12 months (a possible 127.27% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verrica Pharmaceuticals (VRCA)?
The latest analyst rating for Verrica Pharmaceuticals (NASDAQ:VRCA) was provided by Needham, and Verrica Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Verrica Pharmaceuticals (VRCA)?
The last upgrade for Verrica Pharmaceuticals Inc happened on July 25, 2023 when Needham raised their price target to $10. Needham previously had a hold for Verrica Pharmaceuticals Inc.
When was the last downgrade for Verrica Pharmaceuticals (VRCA)?
The last downgrade for Verrica Pharmaceuticals Inc happened on May 25, 2022 when RBC Capital changed their price target from $16 to $4 for Verrica Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Verrica Pharmaceuticals (VRCA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verrica Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verrica Pharmaceuticals was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
Is the Analyst Rating Verrica Pharmaceuticals (VRCA) correct?
While ratings are subjective and will change, the latest Verrica Pharmaceuticals (VRCA) rating was a reiterated with a price target of $16.00 to $16.00. The current price Verrica Pharmaceuticals (VRCA) is trading at is $7.04, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.